New research in adults with HIV suggests semaglutide could influence aging markers, but experts urge caution.
Three things to remember
- Semaglutide slowed biological aging markers in adults with HIV.
- First clinical evidence the drug may influence human aging.
- Larger studies needed before confirming anti-aging effects.
How to interpret it
Historical Biophysics & Lineage
Semaglutide, a GLP-1 receptor agonist, reduces systemic inflammation (inflammaging) by inhibiting NF-κB and lowering pro-inflammatory cytokines, which in turn slows the accumulation of epigenetic damage measured by Horvath’s clock. Additionally, it improves metabolic health (insulin sensitivity, lipid profiles) and reduces cellular senescence, aligning with Finch’s inflammaging theory. In HIV, chronic immune activation accelerates aging; semaglutide’s anti-inflammatory and metabolic effects may counteract this, as reflected in slowed epigenetic aging markers.
Ancestral parallel: Traditional lifestyle practices such as intermittent fasting and calorie restriction (common in ancestral hunter-gatherer diets) naturally increase endogenous GLP-1 secretion, which mimics semaglutide’s effects. These practices reduce inflammation and improve metabolic health, paralleling the drug’s mechanism. The Okinawan concept of ‘Hara Hachi Bu’ (eating until 80% full) and traditional fasting in various cultures (e.g., Ramadan) similarly enhance GLP-1 and autophagy, supporting longevity through the same pathways.
Source
This signal is based on Popular weight-loss drugs Ozempic and Wegovy may slow biological aging from ScienceDaily Healthy Aging. Read the original report for full context.
Health note: Findings are preliminary; not a proven anti-aging treatment.